Patients who take the autoimmune disease treatment Humira may see some price relief when several lower-cost, biosimilar versions of the AbbVie drug reach the U.S. market in July.
may see some price relief when several lower-cost, biosimilar versions of the AbbVie drug reach the U.S. market in July.
It’s an injectable biologic drug used to treat rheumatoid arthritis, Crohn’s disease and ulcerative colitis. Patients usually take it twice a month. A biosimilar is a lower-cost version of a biologic that is approved by the Food and Drug Administration after regulators determine that it is highly similar to the original product. It’s not the same as a generic drug, which is a copy of a chemical-based medicine that is easier - and cheaper - to make.
The pharmacy benefit manager Optum Rx says it will add biosimilars from Boehringer Ingelheim and Sandoz, a division of the drugmaker Novartis, to its standard national formulary, or list of covered drugs, starting July 1.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Cheaper competition for Humira is hitting the market, but savings will depend on your insurancePatients who take the autoimmune disease treatment Humira may see some price relief when several lower-cost, biosimilar versions of the AbbVie drug reach the U.S. market in July.
続きを読む »
Fourth of July 2023: Where to attend July 4 parades in N.J.Check out this list of Fourth of July parades planned throughout New Jersey in 2023.
続きを読む »
CapMetro to suspend fares July 4th after 5 p.m.Following July 4th, CapMetro Rail service will be suspended from July 5-14 for Track Maintenance
続きを読む »
Alaska State Troopers to increase enforcement during Independence Day weekThis heightened enforcement period is scheduled to run from Saturday, July 1 through Wednesday, July 5.
続きを読む »
'High tick population' forces delay of Pleasure Beach opening in BridgeportThe scheduled Fourth of July opening has been postponed to July 8.
続きを読む »